Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49

Trial Profile

Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine In Healthy Adults Aged 18 to 49

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2013

At a glance

  • Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Most Recent Events

    • 08 Aug 2011 Results published in Vaccine.
    • 13 Jan 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Actual patient number (4648) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top